



Seroquel XR® (quetiapine) – First-time Generic

- On November 1, 2016, [Par](#) and [Accord](#) launched generic versions of AstraZeneca's [Seroquel XR \(quetiapine\)](#) extended-release (ER) tablets.
 - Par launched the 50 mg, 150 mg, 200 mg and 300 mg ER tablets and was granted 180 days of exclusivity.
 - Accord launched the 400 mg ER tablet and was granted 180 days of exclusivity.
- Seroquel XR is indicated for the following:
 - Treatment of schizophrenia
 - Acute treatment of manic or mixed episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex
 - Acute treatment of depressive episodes associated with bipolar disorder
 - Maintenance treatment of bipolar I disorder, as an adjunct to lithium or divalproex
 - Adjunctive therapy to antidepressants for the treatment of major depressive disorder
- Seroquel XR carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis, and suicidal thoughts and behaviors.
- According to IMS Health data, U.S. sales of Seroquel XR for the four dosage strengths to be marketed by Par are approximately \$911 million for the 12 months ended September 30, 2016.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at optum.com.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.